Magnetic resonance spectroscopy (MRS) affords a noninvasive window on in vivo brain chemistry and, as such, provides a unique opportunity to gain insight into the biochemical pathology of bipolar disorder. Studies utilizing proton ( 1 H) MRS have identified changes in cerebral concentrations of N-acetyl aspartate, glutamate/glutamine, choline-containing compounds, myo-inositol, and lactate in bipolar subjects compared to normal controls, while studies using phosphorus ( 31 P) MRS have examined additional alterations in levels of phosphocreatine, phosphomonoesters, and intracellular pH. We hypothesize that the majority of MRS findings in bipolar subjects can be fit into a more cohesive bioenergetic and neurochemical model of bipolar illness that is both novel and yet in concordance with findings from complementary methodological approaches. In this review, we propose a hypothesis of mitochondrial dysfunction in bipolar disorder that involves impaired oxidative phosphorylation, a resultant shift toward glycolytic energy production, a decrease in total energy production and/or substrate availability, and altered phospholipid metabolism. Molecular Psychiatry (2005) 10, 900-919.
Bipolar disorder remains a prevalent and serious psychiatric disorder. 1 Although a number of pharmacological treatments for bipolar disorder exist, including mood stabilizers such as lithium and valproic acid, none have emerged as singularly effective against all aspects of the illness. Furthermore, the large range of available remedies implies a poor understanding of the underlying pathophysiology of bipolar disorder.
Magnetic resonance spectroscopy (MRS) affords a noninvasive window on in vivo brain chemistry and, as such, provides a unique opportunity to gain insight into the biochemical pathology of bipolar disorder. Studies utilizing proton ( 1 H) MRS have identified changes in cerebral concentrations of N-acetyl aspartate (NAA), glutamate/glutamine (Glx), choline (Cho)-containing compounds, myo-inositol (mI), and lactate in bipolar subjects compared to normal controls, while studies using phosphorus ( 31 P) MRS have examined additional alterations in levels of phosphocreatine (PCr), phosphomonoesters (PMEs), and intracellular pH (pHi). However, published reports have generally focused on only one such abnormality at a time, and there remains a lack of coherent models to unify this wide variety of biochemical findings.
It is our hypothesis that the majority of MRS findings in bipolar subjects can be fit into a more cohesive bioenergetic and neurochemical model of bipolar illness that is both novel and yet in concordance with findings from complementary methodological approaches. In this review, we propose a hypothesis of mitochondrial dysfunction in bipolar disorder that involves impaired oxidative phosphorylation, a resultant shift toward glycolytic energy production, a decrease in total energy production and/or substrate availability, and altered phospholipid metabolism ( Figure 1 ). This new understanding of bipolar illness as a matter of possible mitochondrial dysfunction has the potential both to lead to more sophisticated diagnostic techniques and to point toward innovative and hopefully more effective treatments.
Reduced N-acetyl-aspartate in bipolar disorder: marker of mitochondrial dysfunction Some of the earliest MRS findings in support of a mitochondrial dysfunction hypothesis of bipolar disorder are the repeated observations of decreased cerebral NAA in bipolar subjects compared to normal controls ( Table 1) . As the most prominent metabolite peak on the 1 H spectrum, NAA levels are typically reported as a ratio using the total creatine signal (creatine plus phosphocreatine, Cr þ PCr) as an internal reference peak (NAA/Cr þ PCr). 2, 3 In healthy individuals, NAA is present in the brain at concentrations of 8-10 mmol/l, 4 and thus follows glutamate as the second most abundant amino acid in the central nervous system. 5 After early research with rat brain mitochondria suggested that NAA is of mitochondrial origin, 6 Truckenmiller et al 7 demonstrated that NAA is synthesized in mitochondria by the membrane-bound enzyme L-aspartate N-acetyltransferase, a catalyst that is found only in the brain ( Figure 2 ). Further studies also indicated that the synthesis of NAA is energy dependent, and stimulated by adenosine diphosphate (ADP). 6 Despite its prevalence in the human brain, the exact function of NAA remains unclear. Some studies have indicated that NAA may play a role in the provision of carbon for lipid and myelin formation, 8 and other research suggests that NAA may be instrumental in protecting neurons against osmotic stress. 8, 9 It has also been suggested that NAA may serve as a readily available precursor of N-acetyl aspartyl glutamate (NAAG), a molecule with neurotransmitter-like properties. 10 Most recently, however, Madhavarao et al 11 have proposed a model in which the synthesis of NAA is an important component of the 'mini citric acid cycle. ' In this process, the extra demand for ATP in neurons is largely met by the oxidation of glutamate via the aspartate aminotransferase pathway. By converting one of the products of this cycle, aspartate, into NAA, NAA biosynthesis is thought to help steer the reaction toward continuing energy production. Additionally, NAA is able to substitute for citrate as an acetate carrier to the cytoplasm, since citrate is not produced during the mini citric acid cycle. In this way, NAA is hypothesized to play an integral role in the energetics of neuronal mitochondria ( Figure 2 ). 11 Consequently, although reductions in NAA concentration were formerly thought to indicate neuronal death, 12 recent research has suggested that decreased levels of NAA are more accurately consistent with impaired mitochondrial energy production. 8, 13 For example, although traumatic brain injury (TBI) is associated with immediate reductions in NAA, several studies have reported that these levels appear to recover significantly with time, which could not occur if NAA levels were decreased by cell death alone. 13, 14 In fact, research on cerebral injury by Demougeot et al 15 has indicated that cellular dysfunction can actually cause greater measurable reductions in NAA than neuronal loss. Abnormally low ratios of NAA/Cr þ PCr have been observed in patients with a number of mitochondrial encephalomyopathies, 16 and studies using mitochondrial respiratory chain inhibitors have also shown that reductions in NAA are correlated with decreases in O 2 consumption and ATP production. 7, 14, 17 When taken together, these studies suggest that NAA levels are closely related to mitochondrial energy metabolism, and thus may serve as a measure of mitochondrial function. 8, 17, 18 A number of 1 H MRS studies have demonstrated reduced NAA levels in patients with bipolar disorder compared to normal controls 2, 5, [19] [20] [21] ( Table 1) . Although the use of Cr as a reference peak has been criticized due to observations of alterations in this signal following treatment with lithium and/or sodium valproate, 22 findings of decreased NAA/ Cr þ PCr ratios in bipolar subjects have been corroborated by observations of similarly significant reductions in NAA levels measured relative to voxel H 2 O levels. 5, 19 Furthermore, a number of studies have noted negative correlations between NAA/Cr þ PCr or NAA levels and illness duration, 2, 5, 20 which implies that reductions in NAA levels in bipolar subjects may become more pronounced with time. If NAA concentration is interpreted as a measure of mitochondrial function, the collected findings of decreased NAA in bipolar subjects compared to normal controls serve as support for a theory of mitochondrial dysfunction in bipolar illness.
Researchers have also investigated whether observations of reduced NAA in bipolar subjects may be due to various treatments for the disorder, in particular lithium administration. However, several trials have suggested that lithium administration actually increases NAA levels in the brain [23] [24] [25] (Table  2 ). A number of 1 H MRS studies have reported increased NAA/Cr þ PCr and absolute NAA levels associated with lithium administration not only in bipolar subjects, [23] [24] [25] but also in healthy controls. Even in contrast with these results, studies led by Brambilla et al 26 in healthy individuals and by Friedman et al 27 in bipolar subjects have found that lithium administration does not appear to be associated with significant differences in NAA concentration. Thus, there remains a lack of MRS evidence that lithium administration is associated with the reduced NAA levels repeatedly observed in bipolar subjects. Consequently, it is more probable that these reports may reflect an underlying-and possibly mitochondrial-pathophysiology to bipolar illness.
It is important to note that decreased cerebral NAA levels in bipolar patients have not been observed in all MRS investigations. Unaltered NAA levels in bipolar subjects have been observed by Ohara 30 were only given a 1 week medication washout period. Since there is evidence that lithium administration may increase NAA levels in bipolar subjects, 24 it is possible that the results of these three studies were confounded by the history of lithium treatment in their subject populations. Additionally, a further seven of the subjects in the study by Hamakawa et al 29 were receiving other pharmacological treatments; only three bipolar subjects were effectively medication free. Consequently, it is also possible that the unaltered NAA levels observed in these studies were due to the normalizing effects of these unidentified treatments.
In contrast with the majority of published MRS research on bipolar disorder, one study by Deicken et al 31 reported increased thalamic NAA in male bipolar subjects compared to normal controls. However, all but two of the bipolar subjects in this study were taking maintenance medications such as lithium and divalproex, which may have contributed to the observed increases in NAA. 24, 31 Furthermore, since positron emission tomography (PET) studies have reported increases in the concentration of thalamic monoaminergic synaptic terminals in bipolar patients, 32, 33 it is possible that Deicken et al's 31 observations of increased thalamic NAA were due to increased synaptic density rather than metabolic abnormality. Similarly, with regard to the findings of Ongur et al 34 of regionally reduced glial cell number and density in patients with bipolar disorder, it is also possible that Deicken et al's 31 findings may be due to glial cell hypoplasia in the thalamus. Further studies are required to fully evaluate these possibilities.
As described, findings of decreased NAA in bipolar disorder have been replicated across numerous subject groups by a variety of different research teams (Tables 1 and 2 ). Together, these studies provide intriguing support for the possibility of mitochondrial involvement in the pathophysiology of bipolar disorder.
Mitochondrial dysfunction in bipolar disorder: evidence for a glycolytic shift MRS research has also provided insight into the possible nature of mitochondrial impairment in bipolar disorder. Specifically, findings of both Mitochondrial dysfunction in bipolar disorder C Stork and PF Renshaw decreased pHi and increased levels of lactate in bipolar subjects suggest a shift away from oxidative phosphorylation toward glycolysis, thus reducing efficiency and reducing total energy output ( Figure 2 ).
Decreased intracellular pH in bipolar disorder
As reported by Kato and co-workers, at the present time, reduced pHi has only been observed in pathological states that are known to arise from ischemic insult to the brain, including white matter hyperintensities, 35 acute stroke, 36 and subarachnoid hemorrhage. 37 Additionally, recent research has confirmed that mitochondrial dysfunction plays a central role in ischemic injury, especially in cases of reperfusion following cerebral ischemia. [38] [39] [40] [41] [42] [43] [44] Consequently, findings of decreased pHi in bipolar subjects compared to normal controls suggest that impaired mitochondrial function may be an integral component of bipolar illness. 31 P MRS research has not only consistently reported reduced pHi in bipolar subjects, but has also suggested that this alteration may be state dependent (Table 3) . Several studies have found significantly reduced pHi in both the basal ganglia 45 and whole brain [45] [46] [47] [48] [49] of bipolar subjects in the euthymic state. However, some of these same studies also indicated that bipolar subjects in the depressed 47 or manic states 46 had significantly higher pHi than euthymic patients. Furthermore, since pHi has been shown to be significantly correlated with duration of lithium treatment, 50 and lower pHi to be associated with a better response to lithium, 51 it is unlikely that reduced pHi in euthymic bipolar subjects is due to lithium administration. Instead, Kato and Kato 52 have hypothesized that the decreased pHi observed in euthymic bipolar subjects is a trait of the illness itself. Specifically, these researchers have suggested that manic and depressive states may be at least partially caused by the brain's attempts to correct this pH imbalance by causing an overactivation of monoaminergic systems, which has been known to increase pHi at least in hippocampal neurons. 53 Such a theory would also thus explain the more normalized pHi of bipolar patients in the manic and depressive states. 52 
Elevated lactate in bipolar disorder
Reductions in cerebral pHi such as those observed in bipolar subjects have also frequently been linked to increased levels of lactate, a condition that is known to result from mitochondrial dysfunction. When mitochondrial function is inhibited, rendering the respiratory chain of cellular metabolism unavailable, the only mode of energy production available to the cell is anaerobic glycolysis. During this process, Mitochondrial dysfunction in bipolar disorder C Stork and PF Renshaw pyruvate is used as a hydrogen acceptor to recover NAD from NADH, thus converting pyruvate into lactate ( Figure 2 ). An increase in lactate concentration therefore suggests an increase in the rate of glycolysis, and consequently also implies an inhibition of the mitochondrial oxidative phosphorylation process; lactate is known to accumulate only when oxidative phosphorylation is unable to meet energy requirements and the cell is forced to rely on the glycolytic process. 54 As a result, elevated lactate levels are commonly used to diagnose and confirm mitochondrial disorders, particularly those that affect the central nervous system. 16, [55] [56] [57] Additionally, animal studies have confirmed that significant increases in brain lactate, as well as decreases in pHi, occur as a result of induced, isolated mitochondrial failure. 58 In one study, in which Clausen et al 58 used cyanide to induce mitochondrial failure in the feline brain, an analysis of corresponding extracellular lactate concentrations and brain tissue pH suggests a logarithmic relationship between the two measure-
Thus, it is possible that seemingly distinct findings of increased lactate and decreased pHi are linked by a common cause of mitochondrial dysfunction.
There have been few MRS studies of lactate in bipolar subjects to date, most likely due to the relatively low concentration of lactate in the human brain (o0.7 mM) as well as difficulties in distinguishing the lactate signal from that of overlapping lipids and macromolecules. 59 However, a recent 1 H MRS study by Dager et al 60 found elevated lactate levels in the gray matter of medication-free bipolar subjects when compared to normal controls. Furthermore, according to the logarithmic relationship suggested by Clausen et al's 58 data of induced mitochondrial failure in felines, the 0.22 mM difference in lactate concentration reported by Dager between bipolar subjects and controls would correspond to a pH difference of approximately 0.016, which is the exact pH difference observed between these two populations in the most recent study of cerebral pHi in bipolar disorder, published by Hamakawa et al. 45 These findings thus suggest that the reduced pHi observed in bipolar subjects may be the result of increased levels of lactate, which is in direct concordance with the hypothesis of a glycolytic shift in bipolar disorder.
Alterations in the glutamate/glutamine cycle: possible applications to bipolar disorder Further insight into the possibility of a glycolytic shift in bipolar disorder has been provided by 1 H MRS studies of the glutamate/glutamine cycle in bipolar subjects. After glutamate is released from nerve terminals, it is taken up by surrounding glial cells and converted to glutamine. This glutamine is then released by the glia, taken up again by the neurons, and converted back into glutamate for further release into the synaptic cleft. A number of investigations have reported increased levels of Glx, the combined signal arising primarily from glutamate and glutamine, in the frontal lobes, basal ganglia, left dorsolateral prefrontal cortex (DLPFC), and global gray matter of drug-free bipolar subjects 30, 60, 61 (Table 4) . Although the Glx peak is difficult to separate into glutamate and glutamine at the relatively low magnetic field strengths used in human studies, 62 an increased Glx signal is likely to imply alterations in the overall glutamate/glutamine cycle.
Findings of increased Glx in bipolar subjects suggest that the hypothesized glycolytic shift underlying the pathology of bipolar disorder may be linked to some degree of glutamate-induced neuronal hyperactivation. As suggested by Dager et al 60 , increased levels of the excitatory neurotransmitter glutamate in the brain would place abnormally large demands on neuronal energy metabolism, similar to but less severe than the excitotoxic mechanism of cell death that occurs during stroke. If cells are unable to meet such Mitochondrial dysfunction in bipolar disorder C Stork and PF Renshaw increased energy requirements through mitochondriabased oxidative phosphorylation, rates of glycolysis would increase, thus causing the increased levels of lactate and decreased pHi observed in studies of bipolar disorder 60 (Table 3) . However, further research is needed to confirm this particular aspect of the mitochondrial dysfunction hypothesis of bipolar disorder.
Relatively few MRS studies have examined the effect of treatment on Glx levels in bipolar patients. However, work by Friedman et al 27 has indicated that lithium administration may have a strong normalizing effect upon Glx levels in bipolar patients, thus precluding any findings of significant differences between bipolar subjects taking lithium and healthy controls. Since the majority of research subjects with bipolar disorder are required to continue maintenance medications for ethical reasons, it is likely that more universal observations of increased Glx in bipolar patients are confounded by the prevalence of lithium and other pharmacological treatments for the illness.
Interestingly, parallel findings of increased glutamate, glutamine, and lactate have lent support to theories of mitochondrial dysfunction in Huntington's disease (HD). 63 Recent research on HD, an autosomal dominant, progressively neurodegenerative disorder, has led to both excitotoxic and energy metabolism theories of pathophysiology. 64 Preclinical studies have suggested that HD can be mimicked in animals with the intrastriatal injection of certain excitotoxins that activate the N-methyl-D-aspartate (NMDA) glutamate receptor, as well as by injection of toxins that block mitochondrial oxidative phosphorylation. 65, 66 Similar to studies of bipolar disorder, 1 H MRS investigations of HD have observed both elevated Glx/Cr þ PCr and lactate in the basal ganglia of HD patients when compared to normal controls 64, 67 In fact, a recent study by Jenkins et al 63 observed significantly increased levels of glutamine in a transgenic mouse model of HD, and described these results as 'evidence of a profound metabolic defect.' It is thus possible that similar MRS findings in bipolar subjects may indicate a similar pathology of excitotoxicity and mitochondrial dysfunction.
Decreased high-energy compounds in bipolar disorder: evidence for impaired energy production
In continuing support of the hypothesis of a glycolytic shift in bipolar disorder, measurements of PCr, the most prominent peak on the 31 P MRS spectrum, 68 have also been found to be altered in bipolar subjects (Table 5 ). Acting as a reservoir for the generation of ATP, the high-energy compound PCr is synthesized from Cr and ATP by the catalyzing agent creatine kinase (CPK) (Figure 2 ). 69 During periods of acute neuronal activity, as molecules of ATP are utilized by Na þ /K þ ATPase, PCr is rapidly broken down in order to maintain the overall concentration of ATP. 69, 70 Although short-term decreases in PCr concentration thus indicate immediate cell activity, as can be observed in episodes of photic stimulation, 71 longterm abnormalities in PCr concentration generally reflect much larger alterations in cellular metabolism, and in particular an insufficient supply of the ATP needed for normal cellular function. 72 In this way, continually decreased levels of PCr are suggestive of hypometabolism, possibly due to mitochondrial dysfunction, and may directly indicate a shift in energy production toward the less-efficient glycolysis. 72, 73 Persistently low brain PCr values have been found in patients with a number of mitochondrial disorders, including mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), Leigh's disease, progressive external opthalmoplegia (PEO), and Leber's hereditary optic atropy. 74, 75 Reduced PCr concentrations have also been reported in migraine, which has been postulated to be associated with abnormal mitochondrial function. 76, 77 Several 31 P MRS studies have suggested a connection between decreased levels of PCr and bipolar disorder (Table 5) . A study by Kato et al 78 of bipolar patients across the full range of mood states (depressed, manic, and euthymic) observed significantly 
However, MRS research in rat brains has indicated that chronic administration of either lithium or sodium valproate can cause a significant decrease in the 1 H Cr þ PCr signal. 22 Consequently, it is possible that the decreased PCr levels observed in these studies were due to the pharmacological effects of these treatments. Of the 40 bipolar patients observed in Kato et al's 78 1995 study, 24 were reported to be taking lithium, and an additional six to be using other therapies. Similarly, the bipolar II patients in Kato et al's 49 1994 study were permitted the use of a range of medications. Nonetheless, these alterations of PCr in bipolar disorder are consistent with some degree of mitochondrial involvement in both the illness and its treatment.
Impaired phospholipid metabolism in bipolar disorder
Further support for a theory of mitochondrial dysfunction in bipolar disorder has arisen from MRS studies of phospholipid metabolism in bipolar subjects. In a normal brain cell, the synthesis and maintenance of the cell membrane require between 10 and 15% of net brain ATP production (Figure 3) . 79 If less energy is produced in the cell overall, it is likely that aspects of phospholipid metabolism, including de novo phospholipid biosynthesis, would also be impaired. Several MRS studies have indicated that phospholipid metabolism is indeed abnormal in bipolar patients, as evidenced by alterations in levels of Cho, mI, inositol monophosphates, and PMEs (Tables 6-10 ). Accordingly, we hypothesize that these alterations are the direct result of energy shortages caused by mitochondrial dysfunction.
Elevated total choline in bipolar disorder: evidence for impaired membrane metabolism One of the most frequently replicated MRS findings in bipolar disorder is that of an increased Cho signal (Table 6 ). This signal, often referred to as 'total Cho,' Mitochondrial dysfunction in bipolar disorder C Stork and PF Renshaw 'Cho-containing compounds,' or 'cytosolic Cho,' consists primarily of phosphocholine (PC) and glycerophosphocholine (GPC), with less than 5% of the signal arising from free Cho itself ( Figure 3) . 59, 80 The total observable Cho concentration in the human brain has been measured at 1-2 mM, with approximately 0.6 mM of PC and 1.0 mM of GPC. [81] [82] [83] [84] Cho is required for the synthesis of both the neurotransmitter acetylcholine and the phospholipid phosphatidylcholine (Figure 3) . Although acetylcholine is produced only by cholinergic neurons, phosphatidylcholine is produced in all cells as a major membrane constituent. 80, 85 Consequently, although small changes in the Cho signal may arise from shuttling between the intracellular and extracellular pools, larger alterations in the Cho signal are generally associated with alterations in membrane synthesis and composition. 59, 80 Significant increases in the Cho resonance are commonly observed in neurodegenerative disorders such as Alzheimer's disease and multiple sclerosis (MS), as well as cases of ischemia and head trauma, presumably due to the liberation of Cho-containing compounds during membrane breakdown. 54, 59, 86 Increased Cho signals can also be associated with cancer, most likely due to the increased cellular density found in tumors. 54, 87 A number of studies have suggested that increased Cho levels may be linked to mitochondrial dysfunction. Perhaps most notably, a 2000 study by Farber et al 88 sought to test the hypothesis that the increased Cho signal observed in Alzheimer's disease is due to accelerated phospholipid turnover ultimately caused by mitochondrial dysfunction. Normal brain cells were treated with the mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) in the presence of glucose, leaving glycolysis as the only mode of energy production. Enhanced phospholipid turnover was confirmed by the observation of an apparent acceleration of the first two enzymatic steps of phosphatidylcholine synthesis, which resulted in an accumulation of CDP-choline and subsequent lack of diacylglycerol, as well as an increased accumulation of the membrane breakdown product GPC. 88 Although further research is required to elucidate the exact mechanisms that underlie these findings, Farber et al H MRS studies have reported elevated Cho/Cr þ PCr ratios and Cho concentrations in bipolar patients compared to healthy controls, particularly in the basal ganglia (Table 6 ). However, additional MRS investigations of both the hippocampus, 5, 21 and DLPFC 2 have reported finding no significant differences in Cho/Cr þ PCr or absolute Cho levels between bipolar subjects and controls. Studies of children with bipolar disorder have similarly noted no significant differences in Cho concentrations between bipolar and control subjects. 20, 30 Nonetheless, it remains possible that findings of increased Cho concentration in bipolar subjects may be indicative of impaired phospholipid metabolism and thus also of mitochondrial dysfunction.
Although studies of human erythrocytes have indicated that lithium exerts a strong and specific inhibitory effect on human Cho transport and, thus, substantially elevates erythrocyte Cho concentrations, 89 several MRS studies have reported little to no association between elevated brain Cho concentration and lithium treatment (Table 7) . A study by Sharma et al 23 reported finding higher Cho/Cr þ PCr in the basal ganglia region of bipolar subjects taking lithium compared to normal controls, but a more recent study by Wu et al 90 contradicted these results by reporting that lithium-treated bipolar patients had significantly lower Cho/Cr þ PCr in the temporal lobe than healthy control subjects. Consequently, if lithium administration does exert a significant effect on brain Cho metabolism, this effect remains to be clarified.
Increased myo-inositol in bipolar disorder: further evidence for impaired membrane metabolism 1 H MRS research has also reported alterations of the mI signal in bipolar subjects (Table 8 ). This signal, one of the three most intense resonances in 1 H MRS, consists primarily of the cyclic sugar alcohol mI, with minor contributions (less than 5%) from various inositol sugar phosphates and glycine (Figure 3 ). 59 In a healthy adult brain, mI concentrations range from 4 to 8 mmol/kg ww , 80 but these levels are known to fluctuate more than any other major compounds in the 1 H spectrum; mI concentrations may reach three times the normal adult values in newborn infants and hypernatremic states and have been observed to drop to almost zero in cases of hepatic encephalopathy. 91 The function of cerebral mI is not entirely understood. mI has been identified as an essential requirement for cell growth, an osmolite, a storage form for glucose, and a possible glial marker. 92, 93 However, mI is widely recognized for its role as precursor to the phospholipid membrane component phosphatidylinositol and as a substrate for the phosphoinositide second-messenger system. 59, 91, 94 Consequently, alterations in mI levels have the potential to reflect abnormalities in both membrane metabolism and intracellular signaling mechanisms. 59 Decreased levels of mI have been observed in cases of chronic hepatic encephalopathy, hypoxic encephalopathy, stroke, tumor, and hyponatremia, 91, 95 while increased concentrations have been observed in conditions such as Alzheimer's disease, diabetes mellitus, recovered hypoxia, hyperosmolar states, and the neonatal brain. 91 Concerning membrane metabolism in particular, abnormally high levels of mI have also been associated with cases of MS plaque, HIV infection, and metachromatic leukodystrophy, and these findings have led some researchers to label mI as a breakdown product of myelin. 91 In the study of affective disorders, mI has most often been examined with regard to its apparent Mitochondrial dysfunction in bipolar disorder C Stork and PF Renshaw involvement in the mechanism of action of lithium. A number of studies have demonstrated that at therapeutically relevant concentrations, lithium is a potent, noncompetitive inhibitor of inositol-1-phosphatase, an enzyme that normally serves to recycle inositol sugar phosphates back into the free inositol pool. This inhibition leads to an accumulation of inositol-1-phosphate (a component of the PME signal in 31 P MRS) and a simultaneous decrease in levels of mI. [96] [97] [98] Since sufficient supplies of mI are necessary both for the re-synthesis of certain membrane components and to maintain the phosphoinositide intracellular signaling system, it has been suggested that lithium achieves its effects through this depletion of the free inositol pool. 99, 100 Several MRS studies have supported this theory with findings of decreased mI levels in subjects undergoing acute lithium administration ( Table 8) .
As lithium continues to be one of the most common and effective pharmacological treatment for bipolar disorder, MRS measurements of mI levels in bipolar subjects must be considered with lithium administration as a confounding factor; observations of both increased or decreased mI concentrations (as well as those of altered PMEs, due to the possible accumulation of inositol-1-phosphate; see the following section) in bipolar individuals may be due to the effects of lithium treatment rather than the disease itself.
Importantly, however, it is also possible that the effect of lithium on inositol and PME levels may not remain constant with continuous administration. Although several studies have demonstrated that acute lithium administration does initially cause a large increase in PME levels (attributed to increased inositol-1-phosphate) and a decrease in mI, 101 Mitochondrial dysfunction in bipolar disorder C Stork and PF Renshaw increased PME levels subsequently decline after 3 weeks of lithium administration. Consequently, since lithium is frequently used as a long-term treatment regimen for bipolar disorder, it is possible that PME levels in individuals with a history of lithium treatment may have normalized after an initial increase. For example, a 2002 study by Silverstone et al 103 found no differences in mI or PME concentrations between bipolar patients under chronic lithium treatment and normal controls, and thus suggested that long-term lithium treatment may normalize the phosphoinositide cycle of individuals with bipolar disorder. Similarly, a study by Brambilla et al 26 of healthy controls before and after lithium administration found no significant differences in mI concentration after 4 weeks of lithium treatment.
Because of the widespread use of lithium, there are few MRS data from bipolar subjects that can be analyzed without regard to its effects (Table 8) . However, one study by Davanzo et al 104 did report increased mI/Cr þ PCr levels in the anterior cingulate of children and adolescents with bipolar disorder who had never been treated with lithium, when compared to normal controls. Sharma et al 23 also reported findings of increased inositol in the basal ganglia of bipolar patients vs comparison subjects, although patients in this study were not lithium free. Additionally, a study by Winsberg et al 2 , in which bipolar patients were reportedly drug free for at least 2 weeks before examination, found a nearly significant trend (P ¼ 0.06) toward higher levels of mI/Cr þ PCr in the right DLPFC 
20 BPs: 10 BP1, 10 BP2; all euthymic and drug free for at least 2 weeks at scan
Trend toward higher mI/Cr þ PCr in right DLPFC (P ¼ 0.06) of BPs vs NCs See Table 1 footnote for abbreviations. PME: phosphomonoester.
Mitochondrial dysfunction in bipolar disorder C Stork and PF Renshaw of bipolar subjects vs controls. Although the confounding effects of lithium cause difficulty in the interpretation of mI levels in bipolar patients, it may yet be argued that elevated mI levels suggest an increase in membrane breakdown and inhibition of membrane metabolism in bipolar disorder that may be caused by mitochondrial dysfunction. 31 P MRS studies of PME levels in bipolar subjects have indicated that some abnormalities in bipolar membrane metabolism may be state dependent, specifically differing during periods of euthymia, mania, and depression (Tables 9 and 10 ). Similar to the multicomponent Cho signal, the PME signal observed by 31 P MRS is the combined product of multiple compounds. In vitro and in vivo assays have determined that the most abundant components of the PME signal are the membrane precursors phosphoethanolamine (PE) and PC, but the signal also includes various sugar and inositol phosphates (Figure 3) . 105, 106 Because of the multiple membrane metabolites represented in this signal, alterations in PME levels are thought to reflect concurrent alterations in phospholipid membrane metabolism. Specifically, an increase of the PME peak has been suggested to indicate an increased rate of membrane phospholipid turnover. 94 Increased PME levels have been observed in the neonate brain, tumors, 36, 107 and the regenerating liver. 108 In contrast, decreased PME levels, possibly reflecting a stagnation or halt of membrane synthesis, have been associated with chronic cerebral infarction, 35 severe demyelinating disorders, 12 anorexia nervosa, 109 and schizophrenia (particularly the negative symptoms thereof). 110, 111 In consideration of the previously noted 1 H MRS findings of increased Cho and mI in bipolar subjects, it is important to recognize the partial inclusion of these metabolites within the PME peak. Specifically, alterations in the Cho or inositol pathways may also be reflected in alterations of the PME signal, since this peak includes both PC (30%) and inositol monophosphates (less than 5%). 112 However, since these various metabolites are only components of the larger PME resonance, PME measurements may provide independently significant insights into phospholipid metabolism.
Unlike many MRS findings in bipolar patients, research on PME levels in bipolar disorder has indicated the possibility of state-dependent changes in concentration. Specifically, while several studies have observed increased PME signals in bipolar patients in the manic or depressed states compared to those in euthymia, a number of investigations have reported decreased PME levels in euthymic bipolar subjects compared to normal controls ( Table 9 ). Many of these findings were also evaluated in a metaanalysis of 31 P MRS research on bipolar disorder by Yildiz et al 113 , which confirmed reports of significantly lower PME levels in euthymic bipolar subjects vs normal controls. One 1998 study by Kato et al 48 did not find a difference in PME levels between euthymic bipolar subjects and controls, but had an extremely small sample group of only seven subjects. It thus remains possible that observations of decreased PME levels in euthymic bipolar patients reflect a general inhibition of membrane synthesis that may be related to mitochondrial impairment.
However, when euthymic bipolar subjects are compared to others in the depressed or manic states, MRS research has illustrated a considerably different picture (Table 10) . Individual studies by Kato et al have reported significantly elevated PME levels in both depressed 47 and manic 46 bipolar subjects compared to those in euthymia, and the later metaanalysis by Yildiz et al 113 also found significantly increased PME levels in depressed vs euthymic bipolar subjects. Like measurements of altered pHi in bipolar subjects (Table 3) , these state-dependent abnormalities in PME concentration may be the result of the brain's attempts to normalize membrane metabolic processes that are impaired due to mitochondrial dysfunction.
As discussed in the previous section, numerous studies have indicated that acute lithium administration is associated with a large increase in PME levels, 101 although it has also been reported that these levels later normalize with continued lithium treatment. 102 Importantly, however, a dual lithium and 31 P MRS study by Kato et al 46 found that PME levels in bipolar patients in both the euthymic and manic states did not correlate with brain lithium concentrations. Additionally, in 1991, Kato et al 114 found PME levels in manic bipolar patients on lithium to be significantly greater than those of euthymic bipolar patients who were also on lithium. Consequently, Kato's team was led to conclude that 'PME levels in the manic state cannot be attributed solely to elevation of brain lithium concentrations.' 46 Instead, observations of both increased and decreased PME levels in bipolar subjects may yet signify abnormal membrane metabolism and thus further support the hypothesis of mitochondrial dysfunction as an underlying pathology of bipolar illness.
Connection to other findings in bipolar research
Although this review has focused on MRS findings in particular, the hypothesis of mitochondrial dysfunction in bipolar disorder is also supported by research using other methodologies. For example, the possibility of mitochondrial dysfunction can be easily linked to the previously developed and more traditional hypotheses of intracellular signaling alterations as key aspects of bipolar pathophysiology. 1 A number of studies of bipolar subjects have reported various abnormalities of second-messenger systems, including alterations in cyclic AMP (cAMP) signaling, 115 protein kinase C (PKC) signaling, 116 and the overall phosphatidylinositol pathway (reviewed by Soares and Mallinger 117 ). In addition, studies have consistently reported that agonist-stimulated calcium response, an important factor in intracellular secondmessenger systems, is enhanced in platelets in patients with bipolar disorder (reviewed by Yamawaki et al 118 ). Given that recent research has demonstrated the important role of mitochondria in sequestering increased intracellular calcium caused by agonist stimulation (reviewed by Simpson and Russell 119 ), it is possible that the mitochondrial dysfunction suggested by MRS research in bipolar disorder is directly related to these previously observed alterations of calcium response and intracellular signaling systems in bipolar patients.
The mitochondrial dysfunction hypothesis of bipolar disorder may also account for the repeated indications of altered cerebral metabolism observed in functional studies of bipolar patients. A number of PET studies have demonstrated that cerebral glucose metabolic rates are significantly decreased in bipolar subjects in depressed or mixed mood states. [120] [121] [122] [123] [124] [125] Additional studies have reported that these low metabolic rates also tend to increase with symptom remission 126 or a shift to a more euthymic or hypomanic state. 125 PET studies of bipolar individuals in the manic state have reported decreased regional cerebral blood flow (rCBF) in the right ventral temporal lobe, 127 orbitofrontal cortex, 128 and frontal regions compared to normal controls, 129 although a 2000 study by Blumberg et al 130 found manic patients to have significant higher rCBF in the left dorsal anterior cingulate cortex (ACC) and left head of the caudate when compared to a separate sample of euthymic bipolar patients. Although PET research cannot identify the etiology of these metabolic differences in bipolar patients, it is possible that they are related to the mitochondrial dysfunction suggested by MRS studies.
Furthermore, investigations of mitochondrial genetics have also found significant evidence of abnormal mitochondrial function in bipolar disorder. Using a quantitative polymerase chain reaction (PCR) method, a 1997 study by Kato et al 131 found a significantly higher ratio of deleted to wild-type mitochondrial DNA (mtDNA) in the cerebral cortex of patients with bipolar disorder compared to agematched controls. After 3 years, Kato et al also reported a significantly higher rate of the 5178C mtDNA genotype, known to be associated with an increased risk and earlier onset of both Alzheimer's and Parkinson's disease, 132 in bipolar patients compared to controls. 133 In addition, bipolar patients with the 5178C genotype exhibited significantly lower brain pHi than patients with the 5178A genotype, 133 which suggests a possible connection between abnormal mtDNA and the reduced pH levels consistently reported in bipolar patients (Table 3) . Finally, in a 2004 study of mRNA expression in the hippocampus of patients with bipolar disorder and schizophrenia compared to healthy controls, Konradi et al 134 found bipolar subjects to have significantly decreased expression of nuclear messenger RNA coding for mitochondrial proteins. Specifically, patients with bipolar disorder were characterized by 'a pronounced and extensive decrease in the expression of genes regulating oxidative phosphorylation and the ATPdependent process of proteasome degradation.' 134 Especially when viewed in light of the MRS evidence presented in this review, these findings considerably strengthen the hypothesis of mitochondrial dysfunction in bipolar disorder.
Conclusion
Although MRS research on bipolar disorder, to date, has largely focused on individual brain metabolite abnormalities, it is our hypothesis that the compilation of these single-compound findings illustrates an intriguing pattern of mitochondrial dysfunction in bipolar illness (Figure 1 ). The integration of such a large and seemingly disparate collection of MRS findings in bipolar subjects into a single theory of mitochondrial dysfunction has enormous potential for advancing the study of bipolar illness, particularly in terms of treatment. Investigations of mitochondriabased neurological disorders, including HD, Parkinson's disease, amyotrophic later sclerosis (ALS), and mitochondrial cytopathies, have led to the development of a number of therapies that target cellular energy dysfunction. 135 If mitochondrial dysfunction is involved in its underlying pathology, such therapies may also prove beneficial in the treatment of bipolar disorder. Studies of HD, an illness with an MRS profile similar to that of bipolar disorder (increased concentrations of lactate, glutamate, and Cho, as well as decreased NAA levels 136 ), have found that Cr supplementation in particular can significantly increase brain concentrations of Cr and ATP to normal levels, thus exerting a neuroprotective effect and slowing the process of brain atrophy. 137, 138 Additional studies of Parkinson's disease and TBI have also investigated the potential use of compounds that may improve cellular energy function, such as coenzyme Q 10 , Gingko biloba, nicotinamide, and lipoic acid, but evidence as to the therapeutic efficacy of these treatments remains extremely limited. 135, 139, 140 Yet if bipolar disorder can be viewed in terms of its possible basis in mitochondrial dysfunction, such therapies have the potential to ameliorate aspects of the disease that are only minimally addressed by current treatment methods.
Furthermore, an understanding of bipolar illness in terms of mitochondrial dysfunction may greatly affect the usage of those treatments currently available. A number of MRS studies have indicated that lithium, the most commonly used pharmacotherapy for bipolar disorder, 1 may increase NAA levels in bipolar subjects (Table 1b) and thus ostensibly improve mitochondrial function, but a study by Silverstone et al 25 reported that this effect is not associated with the administration of sodium valproate. In fact, research on the mechanism of action of valproate has suggested that the drug has a high degree of interference with cellular energy metabolism, and may impair brain fuel utilization (reviewed by Bolañ os and Medina 141 ). Consequently, if bipolar disorder does stem from some degree of mitochondrial dysfunction, it may be important to investigate whether the augmentation of valproate administration with agents that counteract the drug's effects on cellular energetics would improve the clinical efficacy of the treatment regimen as a whole. In addition, research on neuroleptics has indicated that typical and atypical antipsychotics have substantially different effects on respiratory enzyme activity levels. 142 Although typical agents inhibit Complex I of the electron transport chain 143, 144 and thus may cause significant reductions in synaptic ATP synthesis and mitochondrial respiration, 145 atypical agents have comparatively no effect on electron transfer activities. 142 Consideration of the possible mitochondrial factors underlying bipolar disorder may thus prove valuable in the choice and prescription of such antipsychotic treatments.
A recent feature review published in Molecular Psychiatry proposes that novel treatments developed specifically for bipolar disorder will arise from either '(1) understanding the mechanism of action of current medications and thereafter designing novel drugs that mimic these mechanism(s)' or '(2) basing medication development upon the hypothetical or proven underlying pathophysiology of bipolar disorder.' 146 We feel that the hypothesis of mitochondrial dysfunction in bipolar disorder, as supported by evidence from MRS, has the potential to fulfill both these objectives. It remains our hope that, in the future, a better understanding of both current therapies and the underlying pathophysiology of bipolar illness may lead to the development of more sophisticated treatments, and consequently improve the quality of life of thousands of affected individuals.
